Entera Bio Ltd.
ENTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Entera Bio Ltd. focuses on Biotechnology services and products. Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. Valued at $507.6M, ENTX is a small-cap name in its sector. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Market Cap
$507.6M
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-5.31
EPS (TTM)
$-0.36
EPS (Fwd)
$-0.55
ROE
-138.9%
ROA
-46.0%
Cash
$11.3M
Total Debt
$425,000
Free CF
-$6.7M
52W Change
25.3%
Annual Financials
Cash vs Debt
Where ENTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ENTX finished 49.24% above its 150-day moving average ($1.97) and 59.78% above its 200-day moving average ($1.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENTX overbought or oversold?
At the October 20, 2026 close, ENTX's RSI(14) was 57.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Entera Bio Ltd. holds $11.3M in cash against $425K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -138.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $134K (2022) to $42K (2025), a 69% decline worth watching.
With cash comfortably exceeding debt, ENTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ENTX.